Latest Content

Managing Treatment Logistics: Navigating Travel, Lodging and Caregiver Support

March 24th 2025, 8:24pm

By Saad Usmani, MD

Video

Panelists discuss how managing the logistics of multiple myeloma treatment often requires a comprehensive support network, with patients describing complex arrangements for travel to specialized cancer centers, securing temporary lodging near treatment facilities, coordinating caregiver schedules to ensure continual support during intensive therapy periods, navigating insurance and financial assistance programs, and utilizing hospital social workers, patient advocacy organizations and online communities to access resources that ease the burden of treatment-related logistics.

Practical Considerations for Therapies Considered by the Patient and Caregivers in RRMM

March 24th 2025, 8:19pm

By Saad Usmani, MD

Video

Panelists discuss how patients and caregivers considering late-line multiple myeloma therapies must navigate practical considerations including lengthy hospital stays for CAR-T cell therapy (typically two to four weeks), insurance approval challenges, travel to specialized treatment centers, the potential need for caregivers to take extended leave from work, management of posttreatment monitoring requirements, eligibility criteria related to organ function and performance status and planning for potential complications such as cytokine release syndrome or neurological toxicities that might require urgent care access.

Patient’s Experience in Shared Decision Making in RRMM

March 24th 2025, 8:16pm

By Saad Usmani, MD

Video

Panelists discuss how patient involvement in multiple myeloma treatment decisions has evolved from a physician-directed approach to a collaborative partnership, with many patients now actively participating through researching options, joining support groups, asking questions about efficacy and side effects, and working with their health care team to balance quality of life considerations with treatment goals, though the degree of engagement varies based on patient preference, health literacy and physician communication style.

Clinical Factors Evaluated When Choosing Treatment in Late-Line RRMM

March 24th 2025, 8:11pm

By Saad Usmani, MD

Video

Panelists discuss how treatment selection for late-line relapsed/refractory multiple myeloma (RRMM) balances multiple factors including patient fitness, prior therapy exposure, disease aggressiveness, side effect profiles, logistical considerations (with CAR-T requiring hospitalization while bispecifics can often be administered outpatient), financial accessibility and unique toxicity considerations (such as GPRC5D-targeting therapies affecting the skin and nails versus B-cell maturation antigen [BCMA]–targeting approaches), ultimately requiring a personalized approach weighing effectiveness against practical constraints on a patient-by-patient basis.

Current Treatment Landscape for Late-Line RRMM

March 24th 2025, 8:08pm

By Saad Usmani, MD

Video

Panelists discuss how the current treatment landscape for patients with late-line relapsed/refractory multiple myeloma (RRMM) involves novel approaches such as bispecific antibodies, CAR-T cell therapies, antibody-drug conjugates and clinical trials of emerging agents, with treatment selection highly individualized based on prior therapies, resistance patterns and patient-specific factors like comorbidities, quality of life considerations and treatment goals.

Linda’s Treatment History and Challenges in Coping With Multiple Relapses

March 24th 2025, 8:05pm

By Saad Usmani, MD

Video

Panelists discuss how multiple myeloma patients often navigate through numerous treatment regimens over their disease course, frequently cycling through five to 10 different therapeutic approaches since diagnosis, with the greatest challenges being management of cumulative side effects, emotional fatigue from repeated relapses and maintaining hope while facing increasingly limited options as they progress to late-line therapy.

Challenges in Managing Late-Line RRMM

March 24th 2025, 8:03pm

By Saad Usmani, MD

Video

Panelists discuss how the term “late-line” emerged organically in clinical practice to describe patients who had exhausted multiple treatment options, with most experts recalling its growing usage over the past decade as novel therapies expanded the treatment landscape and created a need to distinguish between patients with early and more heavily pretreated relapsed/refractory multiple myeloma (R/R MM).

Dr. Sheri Prentiss on Steps for Lymphedema Screening in Breast Cancer

March 24th 2025, 8:00pm

By Dr. Sheri Prentiss

Video

Dr. Sheri Prentiss discusses what steps patients can take to ensure they're being screened for lymphedema prior to starting their breast cancer treatment.

First Patient Dosed in Phase 3 Trial of IBI354 for Ovarian Cancer

March 24th 2025, 7:00pm

By Spencer Feldman

Article

The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.

How Hope Erased My Fear of Testicular Cancer

March 24th 2025, 5:09pm

By Brian Sluga

Article

Hope helped me navigate my testicular cancer diagnosis at 20, shaping my resilience and guiding my journey as a survivor.

Cretostimogene Has Durable Response in BCG-Unresponsive Bladder Cancer

March 24th 2025, 4:00pm

By Ryan Scott

Article

Cretostimogene treatment shows best-in-class durability of response for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ

Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer

March 24th 2025, 3:00pm

By Alex Biese

Article

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory agencies.

Colorectal Cancer Awareness: Key Signs, Screening and Prevention

March 24th 2025, 1:00pm

By Spencer Feldman

Article

Dr. Zachariah H. Foda discusses key colorectal cancer warning signs, the rise in younger diagnoses and more.

Unraveling Disparities and Genomic Advances Across Breast Cancer Care

March 23rd 2025, 6:00pm

By Ryan Scott

Article

Dr. Regina Hampton shares case studies from her own practice, illustrating how genomic insights have improved patient outcomes in those with breast cancer.

Reducing Bowel Complications Following Radiation in Prostate Cancer

March 23rd 2025, 2:00pm

By Ryan Scott

Article

SpaceOAR Hydrogel reduced the risk of bowel disorders, the need for colonoscopy and rectal resection following radiation therapy in prostate cancer.